We identified IFIX as a new member of the hematopoietic interferon (IFN)-inducible nuclear protein with the 200-amino-acid repeat (HIN-200) family. Six different alternatively spliced forms of mRNA are transcribed from the IFIX gene, which are predicted to encode six different isoforms of IFIX proteins (IFIXa1, a2, b1, b2, c1, and c2). The IFIX proteins are primarily localized in the nucleus. They share a common N-terminal region that contains a predicted pyrin domain and a putative nuclear localization signal. Unlike IFIXa and IFIXb, IFIXc isoforms do not have the 200-amino-acid signature motif. Interestingly, the expression of IFIX was reduced in most human breast tumors and breast cancer cell lines. Expression of IFIXa1, the longest isoform of IFIX, in human breast cancer cell lines reduced their anchoragedependent and -independent growth in vitro and tumorigenicity in nude mice. Moreover, a liposome-mediated IFIXa1 gene transfer suppressed the growth of alreadyformed tumors in a breast cancer xenograft model. IFIXa1 appears to suppress the growth of breast cancer cells in a pRB-and p53-independent manner by increasing the expression of the cyclin-dependent kinase inhibitor p21 CIP1 , which leads to the reduction of the kinase activity of both Cdk2 and p34
Introduction
The interferon (IFN) family of cytokines is known for its growth-inhibitory activity, which plays an important role in IFN-mediated antitumor activity (Kimchi et al., 1988) . Proteins induced by IFN are thought to play important roles in mediating the antitumor activity of IFN (Lengyel, 1993) . family proteins are IFN-inducible proteins that share a 200-amino-acid signature motif of type a and/or b. Three human (IFI16, MNDA, and AIM2) and five mouse (p202a, p202b, p203, p204, and D3) HIN-200 family proteins have been identified (Johnstone and Trapani, 1999; Choubey, 2000) . Genes encoding HIN-200 family proteins are located at chromosome 1q21-23 and form a gene cluster in both mouse and human (Johnstone and Trapani, 1999) . proteins are primarily nuclear proteins involved in the transcriptional regulation of genes important for cell cycle control, differentiation, and apoptosis (Johnstone and Trapani, 1999; Choubey, 2000) . The antitumor activity of HIN-200 proteins has been demonstrated. In particular, we have shown that p202a suppressed tumor growth, reduced tumorigenicity, induced apoptosis, and suppressed metastasis and tumor angiogenesis of human cancer cells (Wen et al., 2000 (Wen et al., , 2001 Ding et al., 2002) . The amino-acid sequence identity between the three human HIN-200 family proteins and the mouse p202a are 40% or less, thus none of these human proteins appears to be the ortholog of p202a. In a search for potential new human HIN-200 proteins, we have identified a new member of the human HIN-200 protein family, IFN-inducible protein X (IFIX). There are at least six IFIX isoforms encoded by alternatively spliced mRNAs (Figures 1a and 2a) . We show here that the mRNA level of IFIX is reduced in breast tumor tissues and breast cancer cell lines and that expression of IFIXa1 reduces growth and tumorigenicity of breast cancer cell lines that have undetectable levels of IFIX expression. We also demonstrate the treatment efficacy of an IFIXa1-based gene therapy in an orthotopic breast cancer model. Together, our data suggest that IFIXa1 functions as a tumor suppressor and may be developed as a therapeutic agent in breast cancer treatment.
Results

IFIX is a novel human HIN-200 gene
To identify potential new human HIN-200 proteins, we used the amino-acid sequence of p202a to query humanspecific nr, est, and htgs databases at National Center for Biotechnology Information (http://www.ncbi.nlm.-nih.gov/) by using the tblastn protocol. These queries identified a new gene IFIX in addition to three previously known human HIN-200 family members, MNDA, IFI16, and AIM2. The IFIX gene is located between MNDA and IFI16 at chromosome 1q21-23. The IFIX cDNAs were obtained by RT-PCR using total RNA isolated from IFN-a-treated Daudi cells. Each cDNA clone was confirmed by DNA sequencing. We identified at least six IFIX isoforms (a1, a2, b1, b2, g1, and g2) that are homologous to other human and mouse HIN-200 proteins (Figure 1a) . The identity between the amino-acid sequence of IFIXa1 and other members of human HIN-200 family is: IFI16, 67%; MNDA, 53%; and AIM2, 31% (Figure 1b) . IFIX is unlikely to be the human ortholog of p202a because the similarity between the amino-acid sequences of IFIX and p202a is only limited to the type a 200-amino-acid signature motif (Figure 1a ). The IFIX isoforms are likely derived from the alternative splicing based on the comparison between the cDNA sequences and the genomic sequence (Figure 2a) . IFIXa2, b2, and g2 have a deletion of identical nine amino acids, that is, 89 VANKIESIP (resulting from alternative splicing), in their N-terminal region when compared to IFIXa1, b1, and g1 (Figure 2b) . The a and b isoforms contain a type a 200-amino-acid signature motif of HIN-200 proteins whereas g isoforms do not have this motif. The Ctermini of a, b, and g isoforms are diverse due to alternative splicing (Figure 2c and d) . The IFIX isoforms share a common N-terminal region, which contains a predicted pyrin domain (amino acids 3-88), a protein-protein interaction module involved in apoptotic and inflammatory signaling pathways (Fairbrother et al., 2001; Martinon et al., 2001; Staub et al., 2001) . In addition, the N-terminal region also contains a putative nuclear localization signal,
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LGPQKRKK (Figure 1b, Dawson and Trapani, 1995) . Consistent with that prediction, we found the stably transfected IFIXa1 as well as the EGFP-tagged IFIXa1, b1, and g1 fusion proteins are localized in the nucleus (Figure 8a and b) . Interestingly, while IFIXa1 and IFIXb1 are primarily localized in the nucleoplasm, IFIXg1 forms a speckled nuclear pattern (Figure 8b ). This observation suggests that, like most of the HIN-200 proteins, the IFIX proteins are primarily nuclear proteins. Consistent with the notion that HIN-200 genes are IFN inducible, the IFIX mRNA levels are characteristically induced by IFN-a and IFN-g in several human cancer cell lines of hematopoietic origin (Figure 3a) . A tissue distribution study showed that IFIX mRNA (B2.4 kb) is readily detected in the spleen, lymph node, and peripheral blood leukocyte, but to a less extent in thymus, bone marrow, and fetal liver (Figure 3b ). No detectable level of IFIX mRNA was found in adult brain, heart, skeletal muscle, colon, kidney, liver, small intestine, placenta, and lung (data not shown). These results suggest that IFIX expression may be involved in immune response.
IFIX is downregulated in human breast cancers
AIM2 has been suggested to play a role in tumorigenesis (De Young et al., 1997) . We therefore investigated whether the expression of IFIX was altered in human cancers. We examined the expression of IFIX using a panel of commercially available human cDNAs derived from 12 normal breast tissues (normal) and 12 breast carcinoma tissues (tumor) (Origene Technologies, Inc. Rockville, MD, USA see Materials and methods) by PCR using primers specific to IFIXa. As shown in Figure 4a , IFIXa expression is detectable in 10 out of 12 normal breast tissue samples. In contrast, only two out of 12 breast carcinoma tissues have detectable IFIXa expression. This result suggests IFIX is downregulated in breast tumors. We further tested this correlation in the matched normal and tumor tissues collected from five breast cancer patients by RT-PCR using primers specific to IFIXa. The expression of IFIXa was detected in all tissues examined however, the level of IFIXa in tumor tissue was lower than that in the normal tissue of each patient (Figure 4b ). We also examined the . These data show that the expression of IFIX is reduced in breast cancer and suggest IFIX may function as a tumor suppressor. To determine the identity of IFIX isoforms in the IFIX-expressing cell lines, we performed RT-PCR using specific primers for these isoforms. As shown in Figure 4d (top and middle panels), the IFIXa, b, and g isoforms are present in these cell lines, although the 27-bp deletion in the 'form 2' isoforms cannot be distinguished at this gel resolution.
To further determine the presence of the 'form 2' isoforms, we designed primers that flank the D27 region (Figure 1b and 2a) followed by RT-PCR. Consistent with the fact that the 'form 2' isoforms were isolated from Daudi cells, the expression of 'form 2' isoforms is detectable in Daudi cells, but the expression levels are much lower than that of the 'form 1' isoforms with the 27-bp region (Figure 4d , bottom panel). However, under 
IFIX a1 suppresses breast cancer cell growth and tumorigenicity
As the first step to investigate the potential role of IFIX in tumor suppression in breast cancer, we use IFIXa1 for subsequent studies because it is the longest isoform of IFIX and possesses the most structural features among IFIX isoforms (Figure 1a and 1b). IFIXa1 is predicted to contain 492 amino acids with an apparent molecular weight of B53 kDa. To investigate the possible tumor-suppressor function of IFIXa1, we employed two human breast cancer cell lines, MCF-7 and MDA-MB-468, which express very low levels of endogenous IFIX (Figure 4c , 5a, and 7b). Consistent with a previous report (Gooch et al., 2000) , we showed that IFN-g treatment suppressed the growth of these breast cancer cells ( Figure 5a , top panel), which correlated with the induction of IFIX ( Figure 5a , bottom panel). To determine whether IFIX could suppress cell growth, we stably expressed IFIXa1 in MDA-MB-468 and MCF-7 cells (Figure 5b ). Examination of the growth rates of the control cell lines (parental (P) and empty vector stable cell line (V)) and two independent IFIXa1-expressing cell lines (X-1 and X-2) derived from MDA-MB-468 and MCF-7 cells showed that the expression of IFIXa1 reduced the growth of breast cancer cells (Figure 5c ). The soft agar assay was used to determine the effect of IFIXa1 on the in vitro transformation property. As shown in Figure 5d , the number of foci of IFIXa1-expressing derivatives (X-1 and X-2) was reduced as compared with the control cell lines (P and V). This result indicated that IFIXa1 suppressed the transformation phenotype of breast cancer cells and predicted a loss of tumorigenicity of IFIXa1-expressing breast cancer cells. To test that possibility, the tumorigenicity of the IFIXa1-expressing derivative 468-X-2 was then investigated by implanting 468-X-2 and the control, MDA-MB-468 cells into the mammary fat pad (MFP) of 6-week-old female nude mice. As shown in Figure 5e , while MDA-MB-468 cells (P) are highly tumorigenic, the tumorigenicity of 468-X-2 cells (X) is significantly reduced. Given that IFN is known to mediate growth inhibition and tumor suppression in breast cancer (Zhang et al., 1996; Coradini et al., 1998; Gooch et al., 2000) , our data suggest that IFIXa1 is a major mediator of the tumorsuppressor activity of IFN. The asterisks represent the statistically significant differences due to the IFN-g treatment. *Po0.0005, **Po0.036. Bottom panel: Total RNAs isolated from MCF-7 and MDA-MB-468 cells treated with or without IFN-g (1000 U/ml) under the same condition as described above were analysed for IFIX expression by RT-PCR. GAPDH was used as an internal control. The IFIXa1 cDNA was used as a specificity control (C). Molecular weight markers (M) are indicated. (b) Expression of exogenous IFIXa1 in breast cancer cell lines. The Flag-tagged IFIXa1 in lysates from clones expressing Flag-tagged IFIXa1 (X-1 and X-2) and the empty vector (pCMVTag2B) (V) control clones were detected by Western blot using an anti-Flag antibody. The actin protein levels serve as loading controls. (c) Reduced growth rates in IFIXa1 stable cell lines. The growth rate of IFIXa1-expressing clones (X-1 and X-2), the parental (P) and the empty vector (V) control clones was measured by MTT assay. Each measurement was made in quadruplicate. The relative absorbance at 570 nm was determined by setting the absorbance on day 1 at 1. The range of variation at some data points is too small to be seen. (d) Suppression of in vitro transformation by IFIX. The parental (P), the empty vector (V), or IFIXa1 stable cell lines (X-1 and X-2) derived from MDA-MB-468 or MCF-7 cells were seeded in soft agar and the colony number was scored at 3 weeks after seeding. The relative colony numbers of IFIXa1-expressing clones are compared with that of their parental cells (100%). (e) Suppression of tumorigenicity by IFIXa1. 468-X-2 and the control, MDA-MB-468 (P) cells were implanted into the MFP of 6-week-old female nude mice at two sites per mouse, three mice per group. The actual size of each tumor at the indicated time points after implantation is presented. Horizontal bars indicate the average tumor size. t-test: *Po0.02
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IFIXa1 treatment results in therapeutic efficacy
To rule out the possibility that the reduced tumorigenicity of 468-X-2 was due to clonal variation ( Figure 5e ) and to test whether IFIXa1 could suppress breast tumor growth, we performed a preclinical gene therapy experiment using an orthotopic breast cancer xenograft model. Female nude mice were inoculated with MDA-MB-468 cells into their MFP and tumors were allowed to grow to 0.5 cm in diameter. Tumors were then injected with the liposome SN2 complexed with either an IFIXa1-expression vector (CMV-IFIXa1) or an empty vector (pCMV-Tag2B). SN2 was selected as the gene delivery system because it is a nonviral, stable liposome-forming cationic lipid formulation and has been proven to be highly efficient in gene delivery (Zou et al., 2002) . As shown in Figure 6 , the CMV-IFIXa1/ SN2 (X) treatment yielded significant antitumor activity as compared to the pCMV-Tag2B/SN2 (V) treatment. This observation suggests that the reduced tumorigenicity seen in 468-X-2 ( Figure 5e ) is likely caused by IFIX expression and not by clonal variation. More importantly, this result indicates that IFIXa1 possesses antitumor activity and shows the feasibility of an IFIX-based gene therapy for breast cancer treatment.
IFIXa1 upregulates p21 cip1
IFN-induced growth arrest is known to be associated with an elevated level of the cyclin-dependent kinase inhibitor (CKI) p21 CIP1 (Naldini et al., 2002; Zhou et al., 2002) . As the expression of IFIXa1 is induced by IFN (Figure 3a and 5a), we therefore investigated the mRNA and protein levels of p21 CIP1 in IFIXa1 stable transfectants. As shown in Figure 7a and b, both p21 CIP1 protein and mRNA levels are upregulated in IFIXa1 stable cell lines (X-1 and X-2) as compared with the control cell lines (P and V). However, there are no detectable changes in the expression of other CKIs, such as p27 KIP1 , p57
KIP2
, and p16
INK4a in IFIXa1-expressing derivatives (data not shown). Since p21 CIP1 is a universal CKI, upregulation of p21 CIP1 should inactivate the kinase activity of Cdk2 in IFIXa1 stable cells. Therefore, we used an immunocomplex kinase assay to determine the Cdk2 kinase activity in IFIXa1 stable cell lines and control cells. As expected, Cdk2 activity is reduced in 468-X-2 and MCF-X-2 as compared to their respective parental cells (Figure 7c ). Western blot indicates that there are comparable amounts of Cdk2 protein used in the kinase assay. However, since MDA-MB-468 cells lack pRB and express mutant p53 , inhibition of MDA-MB-468 cell growth by IFIXa1 cannot simply be attributed to the inactivation of Cdk2 leading to G1/S-phase arrest (MacLachlan et al., 1995) . One possible explanation was that p21 CIP1 also inhibits p34
Cdc2
, a G2/M-phase Cdk (Yu et al., 1998) . We examined the p34
Cdc2 kinase activity in IFIXa1-expressing MDA-MB-468 cells and found that it was much lower than that of the control cells (Figure 7c ). This result suggests that inactivation of p34
Cdc2 may contribute to the IFIXa1-mediated growth inhibition in MDA-MB-468 cells. To further confirm this observation, we performed a flow cytometry analysis to determine any changes in the cell cycle distributions caused by the expression of IFIX. As shown in Figure 7d , a significant G1-phase accumulation and Sphase reduction was observed in MCF-X-2 cells. In contrast, 468-X-2 cells exhibited a significant S-and G2/ M-phase accumulation. This observation not only provides an explanation for the slower growth rate of IFIX stable cell lines (Figure 5c ) but also correlates with the inactivation of Cdk2, leading to G1-phase accumulation in MCF-7 in which pRB/E2F pathway is intact and the inactivation of p34
Cdc2 , resulting in a blockage of G2/M-phase entry in MDA-MB-468 in which pRB/E2F pathway is defective. Together, the data suggest that the p53/pRB-independent p21 CIP1 upregulation contributes to IFIXa1-mediated antitumor activity in breast cancer cells. To test the ability of different IFIX isoforms to induce p21 CIP1 , we transiently transfected MCF-7 cells with the plasmids encoding EGFP-tagged IFIXa1, b1, or g1 fusion protein followed by immunostaining with the p21 CIP1 -specific antibody. As shown in Figure 8b , the expression of IFIXa1 or b1 mainly coincides with the expression of p21 CIP1 in the nucleus (64 and 52%, respectively). In contrast, like the empty vector (EGFP) control, the expression of IFIXg1 has little effect on the expression of p21 CIP1 (0.95 and 2%, respectively). Together with a unique speckled nuclear pattern, our observations indicate that IFIXg1 may function differently from IFIXa1/b1, and it also suggests that the 
Discussion
We identified IFIX as a new member of the human HIN-200 protein family. At least six isoforms were identified in Daudi cells. Interestingly, while the 'form 1' isoforms are present in IFIX-expressing cells such as MCF-10A, MCF-12A, MDA-MB-231, and MDA-MB-435, the 'form 2' isoforms were either missing or undetectable in these cells. A systematic analysis on the expression of 'form 2' isoforms is required to determined whether 'form 2' expression is specific in hematopoietic cells and/or caused by IFN treatment. Using a commercial cDNA expression panel, we found that IFIXa was detectable in only two out of 12 breast carcinomas, whereas most (10 out of 12) of the normal breast tissues have detectable IFIXa expression (Figure 4a ). This result was consistent with that of five pairs of matched normal versus tumor samples we collected from patients in which IFIXa expression is downregulated in all tumor samples as compared with that of the matched normal breast tissue samples (Figure 4b) . Furthermore, seven out of nine breast cancer cell lines examined in this study have no detectable IFIX, while IFIX expression is readily detectable in the nontransformed breast cell lines (Figure 4c) . Although it is possible that the signals on the northern blots may come from other HIN-200 genes due to sequence homology, we consider the IFIXa1 CIP1 mRNA levels in MDA-MB-468 and MCF-7 IFIXa1 stable cells. Total RNA (20 mg) isolated from 468-X-2, MCF-X-2, and the corresponding empty vector (V) control cell lines were analysed by Northern blot using an IFIXa1 or p21 CIP1 probe as indicated. The 18S and 28S rRNA bands on the membrane after transfer stained by ethidium bromide serve as loading control. (c) Inhibition of the kinase activity of Cdk2 and p34
Cdc2 by IFIXa1. Cell lysates isolated from 468-X-2, MCF-X-2, and the parental (P) control cell lines were immunoprecipitated by Cdk2 (or p34 , 1997) . However, the size of IFI16 mRNA is B2.7 kb, it is possible that it may migrate closely with IFIX mRNA. Second, in contrast to the expression of IFI16 mRNA in lymphoid tissues such as spleen, thymus, and peripheral blood leukocyte, and many other organs (Wei et al., 2003) , the expression of IFIX mRNA is clearly restricted to the secondary lymphoid organs such as spleen, lymph nodes, and peripheral blood leukocyte but not the primary lymphoid organs such as thymus and bone marrow (Figure 3b) . Thus, based on the size and tissue distribution patterns of different HIN-200 mRNAs, we believe that, under our experimental conditions, the signals in the Northern blots are mainly generated from the probe hybridizing with IFIX mRNA. Albeit, we cannot rule out the possibility that the additional weak band detected above the IFIX signals in Figure 3b is IFI16 mRNA based on its slightly higher molecular weight and its expression in the thymus. The IFIXspecific antibodies are being generated to detect IFIX proteins by Western blot and immunostaining. Once these critical reagents are available, a more systematic analysis of IFIX protein expression on the breast and normal tumor tissues will be performed to confirm the RT-PCR and Northern blot data presented in this study, and to further investigate the diagnostic and prognostic values of IFIX expression in breast cancer.
To understand how IFIX is downregulated in certain breast tumors or breast cancer cell lines but not in others (Figure 4a and c), further genetic and biochemical analysis is necessary. The expression of HIN-200 was originally identified in hematopoietic cells and was thought to be restricted in this cell type (Dawson and Trapani, 1996) . However, recent reports have shown that IFI16 is expressed in epithelial cells in addition to lymphoid cells (Gariglio et al., 2002; Wei et al., 2003) . Our finding that IFIX expresses in normal breast tissues (Figure 4a and b) and nontransformed breast epithelial cell lines (Figure 4c ) supports the notion that HIN-200 expression is not restricted in hematopoietic cells. Taken together, these observations suggest that IFIX may play a role in maintaining the normal growth of epithelial cells and the downregulation of IFIX expression may contribute to the uncontrolled cell growth and leads to tumorigenesis. It is intriguing that the two breast cancer cell lines that express IFIX, that is, MDA-MB-435 and MDA-MB-231, are metastatic in experimental systems (Price et al., 1990; Zhang et al., 1991) . This observation raises a possible link between IFIX expression and metastatic potential of breast cancer cells. However, this possibility is not supported by the available information. (The manufacturer did not provide the metastasis status of patient samples used in Figure 4a .) Of the five breast tumors we collected from patients, all expressed reduced levels of IFIX (Figure 4b ), including two recurrent metastatic breast tumors in the chest wall (#1 and #2) and three primary breast tumors (#3, #4, and #5). Moreover, except the BT-474 cell line which was isolated from a solid invasive ductal carcinoma, all breast cancer cell lines used for Northern blot analysis shown in Figure 4c were isolated from metastatic breast tumors: MCF-7, T47-D, MDA-MB-435, MDA-MB-231, and MDA-MB-468 (pleural effusion); MDA-MB-361 (brain metastasis); MDA-MB-453 (effusion); and ZR-75-1 (ascitic effusion). Thus, there is no clear correlation between the expression of IFIX and the metastatic potential of breast cancer in human patients.
Compared to the control MDA-MB-468 cells (P and V), MDA-MB-468 derivatives that expressed exogenous IFIXa1 formed fewer colonies in soft agar and resulted in tumors that grew slower in mice, suggesting that IFIXa1 suppresses tumorigenicity (Figure 5d and e) . However, the differences between IFIXa1-expressing derivatives and their parental cells could be due to clonal difference. Moreover, although stably expressing IFIXa1 in breast cancer cell lines are appropriate for proof-ofprinciple experiments, it is inappropriate for predicting treatment outcome in patients. We therefore performed an IFIXa1-based gene therapy to determine if it would yield efficacy in an orthotopic breast cancer xenograft model. As shown in Figure 6 , direct injection of IFIXa1 complexed with the liposome SN2 into tumors yielded a significant antitumor activity as compared to the empty vector control. This result supports the notion that the reduced tumorigenicity of 468-X-2 (Figure 5e ) is caused by IFIXa1 expression and not by clonal difference. Importantly, it clearly demonstrates a feasibility of using IFIXa1 as a potential antitumor agent. Since breast cancer is a metastatic disease, this observation should set the stage for testing the therapeutic efficacy of IFIXa1 in systemic treatments delivered by either SN2 liposome (Zou et al., 2002) or viral vectors (Ding et al., 2002) .
IFN has been shown to increase the expression of p21 CIP1 and this is critical for IFN to suppress the anchorage-independent growth of breast cancer cells (Gooch et al., 2000) . Consistent to that observation, the expression of IFIXa1, an IFN-inducible protein ( Figure  3a and 5a) , reduces the growth of breast cancer cells in soft agar (Figure 5d ) and increases the expression of p21 CIP1 (Figure 7a and b) . This observation suggests that IFIXa1 may mediate p21 CIP1 upregulation in response to IFN. The result that IFIXa1 is able to upregulate p21 CIP1 in MDA-MB-468 cells, which express only mutant p53, indicates the upregulation of p21 CIP1 by IFIXa1 is independent of p53. The p53-independent upregulation of p21 CIP1 has been well documented (Cox, 1997; Nadal et al., 1997; Fang et al., 2000; Hingorani et al., 2000) . In particular, our observation is reminiscent of a previous finding that overexpression of a mouse HIN-200 protein, that is, p202a, also resulted in a p53-independent upregulation of p21 CIP1 (Gutterman and Choubey, 1999) . Since the regulation of p21 CIP1 expression could take place on transcriptional and/or posttranscriptional levels (Funk and Galloway, 1998; Dotto, 2000) , further determination of the half-life of p21 CIP1 mRNA and protein, and the effect on the p21 CIP1 transcriptional activity by IFIX will be necessary to elucidate the mechanism underlying the IFIX-mediated p21 CIP1 upregulation. As expected, the upregulation of p21 CIP1 leads to hypo-phosphorylation of pRB in IFIX-expressing MCF-7 cells (data not shown). However, since MDA-MB-468 cells lack pRB , the inhibition of E2F/pRB pathway by p21 CIP1 cannot account for the mechanism for IFIX-mediated growth inhibition of MDA-MB-468 cells. Our finding that the kinase activity of p34
Cdc2 is reduced in IFIXa1-expressing MDA-MB-468 cells (Figure 7c ) suggests that IFIXa1 may suppress the growth of MDA-MB-468 cells through the inhibition of p34
Cdc2 kinase activity at the G2/M phase of the cell cycle by p21
CIP1 . This interpretation is further supported by the results of flow cytometry analysis (Figure 7d ) that show G1 arrest in IFIXa1-expressing MCF-7 cells in which pRB/E2F pathway is intact because p21
CIP1 upregulation leads to inactivation of Cdk2 and the subsequent activation of pRB, resulting in a blockage at the G1/S-phase transition (Dotto, 2000) . In the case of IFIXa1-expressing MDA-MB-468 cells, although Cdk2 is inactivated, cells progress through G1/ S-phase because pRB/E2F pathway is absent. However, the upregulation of p21 CIP1 also leads to inactivation of p34 Cdc2 , a critical Cdk controlling G2/M transition (Doree and Hunt, 2002) , resulting in S-and G2/Mphase accumulation.
Although it has been shown that two copies of the 200-amino-acid motif of a mouse HIN-200 protein are required for growth inhibition (Gribaudo et al., 1999) , a more recent study showed that the overexpression of a human HIN-200 protein, AIM2, which has only one copy of the type a 200-amino-acid motif, is sufficient to suppress cell growth . Thus, our findings support the notion that, at least in human HIN 200 proteins, a single 200-amino-acid motif is sufficient for growth suppression. Interestingly, IFIXg does not have the characteristic 200-amino-acid signature motif of the HIN-200 family proteins (Figure 1a and 2d) and forms a speckled nuclear pattern (Figure 8b ). Thus, it is likely that IFIXg plays a distinct functional role from a and b isoforms. Indeed, we showed that, while IFIXa1 or IFIXb1 induced p21 CIP1 expression, IFIXg1 did not (Figure 8b ). This result also suggests the 200-amino-acid signature motif may be required for p21 CIP1 upregulation and, possibly, growth suppression. Given that the pyrin domains are known to be involved in protein-protein interactions (Fairbrother et al., 2001; Martinon et al., 2001; Staub et al., 2001) , it is possible that IFIXg may function as a dominant-negative protein by interacting with IFIXa/b or other pyrin domain-containing proteins.
In summary, IFIX, a newly identified HIN-200 gene, is downregulated in breast cancer. The data presented here indicate that IFIXa1 expression is associated with growth retardation, loss of tumorigenicity, and p21 CIP1 upregulation in breast cancer. Moreover, efficacy of an IFIXa1-based gene therapy is demonstrated, raising the possibility of using IFIXa1 as a therapeutic agent in breast cancer treatment.
Materials and methods
Cell lines and plasmids
MCF-10A and MCF-12A cells were maintained in DMEM/ F12 media containing 5% horse serum, 10 mg/ml bovine insulin, 20 ng/ml epidermal growth factor, 100 ng/ml cholera toxin, 0.5 mg/ml hydrocortisone, and 250 ng/ml fungizone. Daudi, Raji, HL-60, and U937 cells were grown in RPMI medium containing 10% fetal bovine serum. All other cell lines were cultured in DMEM/F12 media containing 10% fetal bovine serum. The IFIXa1 expression vector CMV-IFIXa1 was constructed by inserting IFIXa1 cDNA into pCMVTag2B (Flag) (Stratagene, La Jolla, CA, USA). To generate IFIXa1 stable cell lines, CMV-IFIXa1 was transfected into MDA-MB-468 or MCF-7 cells. After 3 weeks of G418 selection (500 mg/ml), the G418-resistant colonies were screened for IFIXa1 expression by Western blot using an anti-Flag antibody (M5, Sigma, St Louis, MO, USA). Control derivatives of MDA-MB-468 and MCF-7 that carry pCMVTag2B were similarly established. The EGFP-IFIX expression vectors were constructed by inserting IFIXa1, b1, and g1 cDNAs into pEGFP-C vectors (BD Biosciences).
Identification and cloning IFIX gene
To identify a new human HIN-200 gene that might be the ortholog of mouse p202, we first used the amino-acid sequence of p202 to query human specific nr, est, and htgs database in the National Center for Biotechnology Information (NCBI) using the tblstn protocol and identified a potential new gene located between MNDA and IFI16 at chromosome 1. As the predicted amino-acid sequence of the new gene appeared to be more homologous to human HIN-200 members than to mouse p202, we then used the IFI16 amino-acid sequence to query these same databases using tblastn. This query allowed us to extend the length of this new gene. Primers were then designed according to the sequences of this potential gene to isolate cDNA by RT-PCR.
Determination of gene expression
The expression of IFIX in cell lines was determined by using Northern blot analysis performed as previously described (Wen et al., 2001) . The expression of GAPDH was used as a control for RNA loading. Human cDNAs derived from 12 normal breast tissues (normal) and 12 breast carcinoma tissues (tumor) (Human Breast Cancer Rapid-Scant Gene Expression Panel, Origene Technologies, Inc. Rockville, MD, USA) were analysed for IFIX expression by PCR using primers specific to IFIXa under the condition suggested by the manufacturer. The IFIXa1 cDNA was used as a DNA template for the IFIXa-specific positive control. b-actin specific primers (provided by the manufacturer) were used to amplify the b-actin-specific band as an internal control. We used RT-PCR to determine the expression of IFIXa in normal and cancerous breast tissues from five patients with various stages of breast cancer including one with only ductal carcinoma in situ. Total RNA was isolated from tissues using Atlas Pure Total RNA Labeling System (BD Biosciences) and reverse transcription was performed using SuperScript Firststrand Synthesis System (Invitrogen, Carlsbad, CA, USA). PCR was performed for 35 cycles at 941C for 40 s, 561C for 1 min, and 721C for 40 s. Primers 5 0 -GGAACAGAGTCAG CATCC-3 0 (exon 7) and 5 0 -CTGCTGGATGGCGGTTGG-3 0 (exon 8) were used to amplified a 224 bp fragment specific to IFIXa (Figure 4a and b) .
In addition, to detect both IFIXa (265 bp) and b (140 bp) isoforms in cell lines (Figure 4d ), the following primers are used: 5 0 -GGAACAGAGTCAGCATCC-3 0 (exon 7) and 5 0 -GTTATTTGATATCCTTGTCC-3 0 (exon 9). To detect IFIXg isoforms (g1, 744 bp and g2, 717 bp), the following primers are used: 5 0 -TTAGAGATGGCAAATAACTAC-3 0 (exon 2) and 5 0 -TTAGTGAGCAAAGGGAATG-3 0 (exon 4 0 ). To detect the expression of the 'form 2' isoforms ('form 1', 161 bp and 'form 2', 134 bp), the following primers are used: 5 0 -TTGGGC AAACTAATAGAATTC-3 0 (exon 2) and 5 0 -GCAGGATA CACTTCTTTCTG-3 0 (exon 3). As a control for the quality of the RNA samples, an B600 bp GAPDH cDNA fragment was amplified using primers 5 0 -TGAAGGTCGGAGTCAACG GA-3 0 and 5 0 -GGCATGGACTGTGGTCATGA-3 0 . To detect all IFIX isoforms (B350 bp) (Figure 5a, bottom panel) , the following primers are used: 5 0 -TGATGGAGGAAAAGTT CC-3 0 (exon 2) and 5 0 -TGCTGGCTCCTGCAGAGC-3 0 (exon 4).
Determination of growth, in vitro transformation and in vivo tumorigenicity of breast cancer cells
MTT and soft agar assays were used to determine the anchorage-dependent and -independent in vitro cell growth, respectively, and were performed as previously described (Shao, 1997) . To measure the effect of IFN-g on cell growth (Gooch et al., 2000) , MCF-7 and MDA-MB-468 cells were planted in 24-well plates (18,000 cells/well) in DMEM/F12 media supplemented with 10% fetal calf serum. The next day, cells were washed in 1 Â PBS and grown in serum-free DMEM/F12 media overnight. The serum-free media was replaced with DMEM/F12 media containing 0.25% fetal calf serum. IFN-g (1000 U/ml) was added. The growth of the cells was measured by MTT assay at 48 h. To determine tumorigenicity, 1 Â 10 6 cells were injected into the MFP of 6-week-old female nude mice and the growth of tumors was monitored weekly. For each experiment, a cell line was injected into three mice with each mouse injected at 2 MFP.
IFIX a1 gene therapy
One million MDA-MB-468 cells in 200 ml of PBS were injected into a MFP of 4-5-week old female nude mice. Each cell line was injected into 5 mice with each mouse injected at 2 MFP. After the tumors grew to 0.5 cm in diameter, mice were treated twice a week by intratumoral injection. Tumor-bearing mice were randomly divided into two equal treatment groups with each tumor injected with 22.5 ml of the liposome SN2 in 50 ml of PBS (Zou et al., 2002) mixed with 15 mg of either CMVIFIXa1 or a control vector pCMV-Tag2B (100 ml total injection volume).
Histone H1 kinase assay
Cells were lysed with RIPA-B buffer (20 mM Na 2 PO 4 (pH 7.4), 150 mM NaCl, 1% Triton X-100, 100 mM NaF, 2 mM Na 3 VO 4 , 5 mM phenylmethylsulfonyl fluoride, 1% aprotinin). Lysate containing 200-400 mg of protein was incubated at 41C for 1 h with 2 mg of anti-Cdk2 antibody (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA) or 1.5 mg antip34
Cdc2 antibody (Santa Cruz Biotech.), followed by incubation with Protein A-agarose for 2 h. The immunoprecipitates were washed twice with PBS, once with kinase buffer (10 mM Tris (pH 7.4), 150 mM NaCl, 10 mM MgCl 2 , and 0.5 mM dithiothreitol), and then resuspended in 40 ml of kinase buffer containing 2 mg of histone H1 (Sigma), 25 mM ATP, and 5 mM g-32 P ATP. The kinase reaction was terminated by adding 40 ml of SDS-PAGE loading buffer after a 15 min incubation at room temperature (Cdk2) or 30 min incubation at 301C (p34
Cdc2
). Samples were resolved by SDS-PAGE and the phosphorylated Histone H1 was visualized by autoradiography.
Western blot
The standard procedure has been described previously (Wen et al., 2001) . The antibodies used in this study are anti-Flag (Sigma, M5), anti-b-actin (Sigma), anti-p21 CIP1 (Santa Cruz Biotech.), anti-poly-(ADP-ribose) polymerase (PARP) (BD Biosciences), and anti-a-Tubulin (Sigma). The cytoplasmic and nuclear extracts were isolated according to the protocol described previously (Xie and Hung, 1994) .
Immunostaining MCF-7 cells (1 Â 10 4 in 0.5 ml). were cultured in a four-well glass chamber overnight. Cells were then transfected with 1 mg of the plasmid encoding EGFP-tagged IFIXa1, b1, or g1 fusion protein. The EGFP expression vector serves as a control. At 48 h after transfection, cells were washed with PBS and fixed with 3% paraformaldehyde in PBS for 20 min at room temperature followed by PBS wash. The primary p21 CIP1 monoclonal antibody (Santa Cruz Biotech.) (1 : 100) was incubated with the cells at 371C for 1 h. Cells were then washed with PBS, followed by incubation with the rabbit antimouse secondary antibody conjugated with Texas Red (1 : 200) at 371C for 45 min. After incubation, cells were washed briefly with PBS and air-dried, followed by incubation with the blue fluorescent dye DAPI (1 : 100 in 50% glycerol/PBS). A cover slip was placed on top of the slide for visualization by microscopy.
GenBank Accession numbers
IFIXa1
(AY185344), IFIXa2 (AY185345), IFIXb1 (AY185346), IFIXb2 (AY185347), and IFIXg1 (XM086611).
Note Added In Proof
During the preparation of this manuscript, a partial amino acid sequence of the N-terminal domain of IFIX protein (referred to as IFI16-like protein 1) was published (Liepinsh et al., 2003) .
